Artiva Biotherapeutics, Inc. ARTV Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers SquibbBMY

$207M+6.7%

Kyverna Therapeutics, Inc.KYTX

$1.76M-42.7%

Immix Biopharma, Inc.IMMX

$125.39K+84.9%

ImmunityBio, Inc.IBRX

$7.63M+2.2%

Cullinan Therapeutics, Inc.CGEM

$666K-52.2%

Nektar TherapeuticsNKTR

$22.53M+3.2%

FAQ

What is Artiva Biotherapeutics, Inc.'s operating lease liabilities (current)?

Artiva Biotherapeutics, Inc. (ARTV) reported operating lease liabilities (current) of $3.3M in Q2 2026.

How has Artiva Biotherapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?

Artiva Biotherapeutics, Inc.'s operating lease liabilities (current) decreased by 6.7% year-over-year, from $3.54M to $3.3M.

What is the long-term trend for Artiva Biotherapeutics, Inc.'s operating lease liabilities (current)?

Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s operating lease liabilities (current) has grown at a -8.4% compound annual growth rate (CAGR), from $3.6M to $3.02M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.